NO20073636L - Sammensetninger og metoder til a behandle mentale lidelser - Google Patents

Sammensetninger og metoder til a behandle mentale lidelser

Info

Publication number
NO20073636L
NO20073636L NO20073636A NO20073636A NO20073636L NO 20073636 L NO20073636 L NO 20073636L NO 20073636 A NO20073636 A NO 20073636A NO 20073636 A NO20073636 A NO 20073636A NO 20073636 L NO20073636 L NO 20073636L
Authority
NO
Norway
Prior art keywords
schizophrenia
bipolar disorder
disorders
compositions
methods
Prior art date
Application number
NO20073636A
Other languages
English (en)
Inventor
Ilya Chumakov
Daniel Cohen
Fabio Macciardi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20073636L publication Critical patent/NO20073636L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Den foreliggende oppfinnelse angår generelt fremgangsmåter og sammensetninger for å detektere eller behandle mentale lidelser, så som schizofreni eller bipolar hdelse. Den foreliggende oppflnnelse beskriver mer spesielt identiflkasjon av humane gener som kan anvendes for diagnose, forhindring og behandling av schizofreni, bipolar lidelse og beslektede lidelser, så vel som for screening av terapeutisk aktive medikamenter for å behandle nevnte lidelser. Oppflnnelsen beskriver videre spesiflkke polymorflsmer eller alleler av KCNQ3-genet som er relatert til schizofreni eller bipolar lidelse, så vel som diagnostiske verktøy og sett basert på disse markører. Oppflnnelsen kan anvendes til diagnose av eller disposisjon for, deteksjon, forhindring og/eller behandling av schizofreni, bipolar lidelse og beslektede lidelser.
NO20073636A 2004-12-24 2007-07-13 Sammensetninger og metoder til a behandle mentale lidelser NO20073636L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04293130 2004-12-24
PCT/EP2005/056660 WO2006067056A1 (en) 2004-12-24 2005-12-09 Compositions and methods for treating mental disorders

Publications (1)

Publication Number Publication Date
NO20073636L true NO20073636L (no) 2007-07-13

Family

ID=34931662

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073636A NO20073636L (no) 2004-12-24 2007-07-13 Sammensetninger og metoder til a behandle mentale lidelser

Country Status (8)

Country Link
US (1) US20070249518A1 (no)
EP (1) EP1828413A1 (no)
JP (1) JP2008524999A (no)
AU (1) AU2005318278A1 (no)
CA (1) CA2578071A1 (no)
IL (1) IL183931A0 (no)
NO (1) NO20073636L (no)
WO (1) WO2006067056A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075789A1 (en) * 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EP2437744B1 (en) * 2009-06-03 2015-06-03 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
DE102013108763A1 (de) 2013-08-13 2015-03-26 Krones Ag Vorrichtung und Verfahren zum Erwärmen von Kunststoffvorformlingen mit veränderter Teilung bei Vorformlingsübergabe
WO2020092577A1 (en) * 2018-10-30 2020-05-07 The Trustees Of Columbia University In The City Of New York Treatment of kcnq2 and kcnq3 gain of function-associated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175691A1 (en) * 1998-12-03 2004-09-09 Brown Barry S. Use of the KCNQ2 and KCNQ3 genes for the discovery of agents useful in the treatment of neurological disorders
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
JP2005501536A (ja) * 2001-07-18 2005-01-20 バイオノミックス リミテッド イオンチャネルにおける変異
EP1581498A2 (en) * 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers

Also Published As

Publication number Publication date
US20070249518A1 (en) 2007-10-25
JP2008524999A (ja) 2008-07-17
CA2578071A1 (en) 2006-06-29
EP1828413A1 (en) 2007-09-05
WO2006067056A1 (en) 2006-06-29
AU2005318278A1 (en) 2006-06-29
WO2006067056A9 (en) 2006-10-19
IL183931A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
NO20073636L (no) Sammensetninger og metoder til a behandle mentale lidelser
EP1899486A4 (en) METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY
WO2003082210A3 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
WO2005067391A3 (en) Diagnostic test for parkinson's disease
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ATE415175T1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
WO2008143774A3 (en) Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008033461A3 (en) Methods for the identification, evaluation and treatment of patients having cc-chemokine receptor 2(ccr-2) mediated disorders
MA30485B1 (fr) Aminothiazoles et leurs utilisations
WO2004026107A3 (en) Kits and methods for assessing skin health
WO2009087689A3 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
Ayada et al. Evaluation of whether the ACE gene I/D polymorphism constitutes a risk factor for chronic obstructive pulmonary disease in the Turkish population
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
WO2009140679A3 (en) Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
MX2009008788A (es) Poliformismos de serpine1 son predictivos de respuesta a administracion de proteina c activada y riesgo de muerte.
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2004005886A3 (en) Kits and methods for assessing cardiovascular health
WO2010008858A8 (en) Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application